(Reuters) - Canadian health regulators have approved GlaxoSmithKline's (L:GSK) key shingles vaccine, the company said on Friday.
Shingrix, the British pharma company's shingles vaccine for people aged 50 years or older, was unanimously recommended for approval by a U.S. Food and Drug Administration (FDA) advisory panel last week.
Older people are most at risk of an outbreak of shingles, a painful, often debilitating blistering rash.
Shingles is the result of reactivation of the varicella-zoster virus, which causes chickenpox and remains latent in those who have had that disease.